Hyderabad: Biological E Limited (BE) announced that its Covid-19 vaccine, CORBEVAX, has been granted Emergency Use Listing (EUL) by the World Health Organisation (WHO).
CORBEVAX, India’s inaugural indigenously developed Covid-19 vaccine utilising the protein sub-unit platform, secured approval in India for emergency use in adults, adolescents, and young children, along with authorisation as a heterologous booster dose for individuals aged 18 and above.
The Drugs Controller General of India (DCGI) granted emergency use authorisation for CORBEVAX in adults, adolescents, and young children from December 2021 to April 2022. Additionally, approval was obtained for using the vaccine as a heterologous booster in those aged 18 years and above in June 2022.
Biological E Ltd, headquartered in Hyderabad, has delivered 100 million doses of CORBEVAX to the Indian government for nationwide immunisation campaigns, focusing on vaccinating children in the 12-14 age group.
Mahima Datla, Managing Director of Biological E Ltd, expressed confidence that the WHO EUL would enable the company to develop Covid-19 vaccines further in response to public health needs.
“Our commitment is to provide affordable and accessible vaccines that are of high quality and the WHO EUL lays a path for us to make that possible,” she said.
Discussion about this post